SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
   Trade name : Abamectin Liquid Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
   Use of the Substance/Mixture : Veterinary product

1.3 Details of the supplier of the safety data sheet
   Company : MSD
   Kilsheean
   Clonmel Tipperary, IE
   Telephone : 353-51-601000
   E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
   1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
   Classification (REGULATION (EC) No 1272/2008)
   Acute toxicity, Category 4 : H332: Harmful if inhaled.
   Specific target organ toxicity - repeated exposure, Category 2 : H373: May cause damage to organs through prolonged or repeated exposure.
   Short-term (acute) aquatic hazard, Category 1 : H400: Very toxic to aquatic life.
   Long-term (chronic) aquatic hazard, Category 1 : H410: Very toxic to aquatic life with long lasting effects.

2.2 Label elements
   Labelling (REGULATION (EC) No 1272/2008)
   Hazard pictograms :
   Signal word : Warning
   Hazard statements :
   H332 Harmful if inhaled.
   H373 May cause damage to organs through prolonged or repeated exposure.
   H410 Very toxic to aquatic life with long lasting effects.
Precautionary statements:

Prevention:
P271 Use only outdoors or in a well-ventilated area.
P273 Avoid release to the environment.

Response:
P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell.
P314 Get medical advice/ attention if you feel unwell.
P391 Collect spillage.

Hazardous components which must be listed on the label:
abamectin (combination of avermectin B1a and avermectin B1b) (ISO)

2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

<table>
<thead>
<tr>
<th>Components</th>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>EC-No.</th>
<th>Index-No.</th>
<th>Registration number</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>abamectin (combination of avermectin B1a and avermectin B1b) (ISO)</td>
<td>abamectin (combination of avermectin B1a and avermectin B1b) (ISO)</td>
<td>71751-41-2</td>
<td>606-143-00-0</td>
<td></td>
<td></td>
<td>Acute Tox. 2; H300 Acute Tox. 1; H330 Acute Tox. 3; H311 Rep. 2; H361fd STOT RE 1; H372 (Central nervous system) Aquatic Acute 1; H400 Aquatic Chronic 1; H410</td>
<td>&gt;= 1 - &lt; 2.5</td>
</tr>
</tbody>
</table>

M-Factor (Acute aquatic toxicity): 10,000 M-Factor (Chronic)
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Abamectin Liquid Formulation

aquatic toxicity): 10,000

specific concentration limit
STOT RE 1; H372 >= 5 %
STOT RE 2; H373 0.5 - < 5 %

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled: If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks: Harmful if inhaled. May cause damage to organs through prolonged or repeated exposure.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment: Treat symptomatically and supportively.
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Abamectin Liquid Formulation

SECTION 5: Firefighting measures

5.1 Extinguishing media
Suitable extinguishing media:
- Water spray
- Alcohol-resistant foam
- Carbon dioxide (CO2)
- Dry chemical

Unsuitable extinguishing media:
- None known.

5.2 Special hazards arising from the substance or mixture
Specific hazards during firefighting:
- Exposure to combustion products may be a hazard to health.

Hazardous combustion products:
- Carbon oxides

5.3 Advice for firefighters
Special protective equipment for firefighters:
- In the event of fire, wear self-contained breathing apparatus.
- Use personal protective equipment.

Specific extinguishing methods:
- Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Use water spray to cool unopened containers.
- Remove undamaged containers from fire area if it is safe to do so.
- Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures
Personal precautions:
- Use personal protective equipment.
- Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions
Environmental precautions:
- Avoid release to the environment.
- Prevent further leakage or spillage if safe to do so.
- Prevent spreading over a wide area (e.g. by containment or oil barriers).
- Retain and dispose of contaminated wash water.
- Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up
Methods for cleaning up:
- Soak up with inert absorbent material.
- For large spills, provide dyking or other appropriate contain-
ment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections
See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation: If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling: Do not breathe mist or vapours.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
Keep container tightly closed.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers: Keep in properly labelled containers. Keep tightly closed.
Keep in a cool, well-ventilated place. Store in accordance with the particular national regulations.

Advice on common storage: Do not store with the following product types:
Strong oxidizing agents
Organic peroxides
Explosives
Gases
7.3 Specific end use(s)
Specific use(s): No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

**Occupational Exposure Limits**

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>abamectin (combination of avermectin B1a and avermectin B1b) (ISO)</td>
<td>71751-41-2</td>
<td>TWA</td>
<td>15 µg/m3 (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>150 µg/100 cm²</td>
<td>Internal</td>
</tr>
</tbody>
</table>

**Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:**

<table>
<thead>
<tr>
<th>Substance name</th>
<th>End Use</th>
<th>Exposure routes</th>
<th>Potential health effects</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glycerides, mixed decanoyl and octanoyl</td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>177.79 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>25.21 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>43.84 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>12.61 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Ingestion</td>
<td>Long-term systemic effects</td>
<td>12.61 mg/kg bw/day</td>
</tr>
</tbody>
</table>

**Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:**

<table>
<thead>
<tr>
<th>Substance name</th>
<th>Environmental Compartment</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glycerides, mixed decanoyl and octanoyl</td>
<td>Oral (Secondary Poisoning)</td>
<td>0.03 mg/kg food</td>
</tr>
</tbody>
</table>

8.2 Exposure controls

**Engineering measures**
Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
Minimize open handling.

**Personal protective equipment**
Eye protection: Wear safety glasses with side shields or goggles.
Abamectin Liquid Formulation

If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection

Material: Chemical-resistant gloves
Remarks: Consider double gloving.

Skin and body protection:
- Work uniform or laboratory coat.
- Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
- Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection:
- If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Equipment should conform to I.S. EN 14387.
- Filter type: Combined particulates and organic vapour type (A-P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical state</td>
<td>liquid</td>
</tr>
<tr>
<td>Colour</td>
<td>light yellow</td>
</tr>
<tr>
<td>Odour</td>
<td>characteristic</td>
</tr>
<tr>
<td>Odour Threshold</td>
<td>No data available</td>
</tr>
<tr>
<td>Melting point/freezing point</td>
<td>No data available</td>
</tr>
<tr>
<td>Initial boiling point and boiling range</td>
<td>No data available</td>
</tr>
<tr>
<td>Flammability (solid, gas)</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Flammability (liquids)</td>
<td>No data available</td>
</tr>
<tr>
<td>Upper explosion limit / Upper flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Lower explosion limit / Lower flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Flash point</td>
<td>No data available</td>
</tr>
<tr>
<td>Auto-ignition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Decomposition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>pH</td>
<td>No data available</td>
</tr>
<tr>
<td>Viscosity</td>
<td></td>
</tr>
</tbody>
</table>

7 / 19
Abamectin Liquid Formulation

Viscosity, kinematic : No data available

Solubility(ies)
  Water solubility : insoluble

Partition coefficient: n-octanol/water
  : Not applicable

Vapour pressure : No data available

Relative density : No data available

Density : 0.90 - 0.94 g/cm³

Relative vapour density : No data available

Particle characteristics
  Particle size : Not applicable

9.2 Other information
  Explosives : Not explosive
  Oxidizing properties : The substance or mixture is not classified as oxidizing.
  Evaporation rate : No data available
  Molecular weight : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity
  Not classified as a reactivity hazard.

10.2 Chemical stability
  Stable under normal conditions.

10.3 Possibility of hazardous reactions
  Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid
  Conditions to avoid : None known.

10.5 Incompatible materials
  Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products
  No hazardous decomposition products are known.
SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity
Harmful if inhaled.

Product:
- Acute oral toxicity: Acute toxicity estimate: > 2,000 mg/kg
  Method: Calculation method
- Acute inhalation toxicity: Acute toxicity estimate: 2.3 mg/l
  Exposure time: 4 h
  Test atmosphere: dust/mist
  Method: Calculation method
- Acute dermal toxicity: Acute toxicity estimate: > 2,000 mg/kg
  Method: Calculation method

Components:
- abamectin (combination of avermectin B1a and avermectin B1b) (ISO):
  - Acute oral toxicity:
    - LD50 (Rat): 24 mg/kg
    - LD50 (Mouse): 10 mg/kg
    - LDLo (Monkey): 24 mg/kg
    - Symptoms: Dilatation of the pupil
  - Acute inhalation toxicity:
    - LC50 (Rat): 0.023 mg/l
    - Exposure time: 4 h
    - Test atmosphere: dust/mist
  - Acute dermal toxicity:
    - LD50 (Rat): 330 mg/kg
    - LD50 (Rabbit): 2,000 mg/kg

Skin corrosion/irritation
Not classified based on available information.

Components:
- abamectin (combination of avermectin B1a and avermectin B1b) (ISO):
  - Species: Rabbit
  - Result: No skin irritation

Serious eye damage/eye irritation
Not classified based on available information.
Abamectin Liquid Formulation

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species: Rabbit
Result: Mild eye irritation

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Test Type: Maximisation Test
Exposure routes: Skin contact
Result: Not a skin sensitizer.

Germ cell mutagenicity
Not classified based on available information.

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Genotoxicity in vitro:
Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster lung cells
Result: negative

Test Type: Alkaline elution assay
Result: negative

Genotoxicity in vivo:
Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative

Carcinogenicity
Not classified based on available information.

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species: Rat
Application Route: Oral
Exposure time: 105 weeks
Result: negative
Abamectin Liquid Formulation

Species: Mouse
Application Route: Oral
Exposure time: 93 weeks
Result: negative

Reproductive toxicity
Not classified based on available information.

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Effects on fertility:
- Test Type: Fertility
- Species: Rat, male
- Application Route: Oral
- Result: Effects on fertility

Test Type: Two-generation reproduction toxicity study
- Species: Rat
- Application Route: Oral
- Early Embryonic Development: NOAEL: 0.12 mg/kg body weight

Result: Fetotoxicity

Effects on foetal development:
- Test Type: Embryo-foetal development
- Species: Mouse
- Application Route: Oral
- General Toxicity Maternal: NOAEL: 0.05 mg/kg body weight
- Developmental Toxicity: NOAEL: 0.2 mg/kg body weight
- Result: Cleft palate
- Remarks: Adverse developmental effects were observed

Test Type: Embryo-foetal development
- Species: Rabbit
- Application Route: Oral
- Developmental Toxicity: LOAEL: 2 mg/kg body weight
- Result: Cleft palate, Teratogenic effects, Reduced embryonic survival
- Remarks: Adverse developmental effects were observed

Test Type: Development
- Species: Rat
- Application Route: Oral
- Developmental Toxicity: LOAEL: 1.6 mg/kg body weight
- Result: Teratogenic effects

Reproductive toxicity - Assessment:
- Some evidence of adverse effects on sexual function and fertility, based on animal experiments.
- Some evidence of adverse effects on development, based on animal experiments.

STOT - single exposure
Not classified based on available information.
STOT - repeated exposure
May cause damage to organs through prolonged or repeated exposure.

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):
Exposure routes: Ingestion
Target Organs: Central nervous system
Assessment: Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):
Species: Rat
NOAEL: 1.5 mg/kg
Application Route: Oral
Exposure time: 24 Months
Target Organs: Central nervous system
Symptoms: Tremors, ataxia

Species: Mouse
NOAEL: 4.0 mg/kg
Application Route: Oral
Exposure time: 24 Months
Target Organs: Central nervous system
Symptoms: Tremors, ataxia

Species: Dog
NOAEL: 0.25 mg/kg
LOAEL: 0.5 mg/kg
Application Route: Oral
Exposure time: 53 Weeks
Target Organs: Central nervous system
Symptoms: Tremors, weight loss
Remarks: mortality observed

Species: Monkey
NOAEL: 1.0 mg/kg
Application Route: Oral
Exposure time: 14 Weeks
Target Organs: Central nervous system

Aspiration toxicity
Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Product:
Assessment: The substance/mixture does not contain components consid-
Abamectin Liquid Formulation

Experience with human exposure

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Ingestion:
Symptoms: May cause, Tremors, Diarrhoea, central nervous system effects, Salivation, tearing

SECTION 12: Ecological information

12.1 Toxicity

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Toxicity to fish:
- LC50 (Oncorhynchus mykiss (rainbow trout)): 3.2 µg/l
  Exposure time: 96 h
- LC50 (Lepomis macrochirus (Bluegill sunfish)): 9.6 µg/l
  Exposure time: 96 h
- LC50 (Ictalurus punctatus (channel catfish)): 24 µg/l
  Exposure time: 96 h
- LC50 (Cyprinus carpio (Carp)): 42 µg/l
  Exposure time: 96 h
- LC50 (Cyprinodon variegatus (sheepshead minnow)): 15 µg/l
  Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates:
- EC50 (Americamysis): 0.022 µg/l
  Exposure time: 96 h
- EC50 (Daphnia magna (Water flea)): 0.34 µg/l
  Exposure time: 48 h

Toxicity to algae/aquatic plants:
- EC50 (Pseudokirchneriella subcapitata (green algae)): 100 mg/l
  Exposure time: 72 h

M-Factor (Acute aquatic toxicity):
- 10,000

Toxicity to microorganisms:
- EC50: > 1,000 mg/l
  Exposure time: 3 h
  Test Type: Respiration inhibition

Toxicity to fish (Chronic toxicity):
- NOEC: 0.52 µg/l
  Exposure time: 32 d
Abamectin Liquid Formulation

Species: Pimephales promelas (fathead minnow)

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):
- NOEC: 0.03 µg/l
- Exposure time: 21 d
- Species: Daphnia magna (Water flea)
- NOEC: 0.0035 µg/l
- Exposure time: 28 d
- Species: Mysisia bahia (oossum shrimp)

M-Factor (Chronic aquatic toxicity): 10,000

12.2 Persistence and degradability

Components:
- abamectin (combination of avermectin B1a and avermectin B1b) (ISO):
  - Stability in water: Hydrolysis: 50 %(< 12 h)

12.3 Bioaccumulative potential

Components:
- abamectin (combination of avermectin B1a and avermectin B1b) (ISO):
  - Bioaccumulation: Bioconcentration factor (BCF): 52
  - Partition coefficient: n-octanol/water: log Pow: 4

12.4 Mobility in soil

Components:
- abamectin (combination of avermectin B1a and avermectin B1b) (ISO):
  - Distribution among environmental compartments: log Koc: > 3.6

12.5 Results of PBT and vPvB assessment

Product:
- Assessment: This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Endocrine disrupting properties

Product:
- Assessment: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Abamectin Liquid Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.7</td>
<td>27.08.2021</td>
<td>1228550-00015</td>
<td>26.04.2021</td>
<td>18.01.2017</td>
</tr>
</tbody>
</table>

12.7 Other adverse effects
No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

<table>
<thead>
<tr>
<th>Product</th>
<th>Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contaminated packaging</td>
<td>Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.</td>
</tr>
</tbody>
</table>

SECTION 14: Transport information

14.1 UN number or ID number

| ADN | UN 3082 |
| ADR | UN 3082 |
| RID | UN 3082 |
| IMDG| UN 3082 |
| IATA| UN 3082 |

14.2 UN proper shipping name

| ADN                          | ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (abamectin (combination of avermectin B1a and avermectin B1b) (ISO)) |
| ADR                          | ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (abamectin (combination of avermectin B1a and avermectin B1b) (ISO)) |
| RID                          | ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (abamectin (combination of avermectin B1a and avermectin B1b) (ISO)) |
| IMDG                         | ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (abamectin (combination of avermectin B1a and avermectin B1b) (ISO)) |
| IATA                         | Environmentally hazardous substance, liquid, n.o.s. (abamectin (combination of avermectin B1a and avermectin B1b) (ISO)) |

14.3 Transport hazard class(es)

| ADN | 9 |
### Abamectin Liquid Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.7</td>
<td>27.08.2021</td>
<td>1228550-00015</td>
<td>26.04.2021</td>
<td>18.01.2017</td>
</tr>
</tbody>
</table>

**ADN**
- Packing group: III
- Classification Code: M6
- Hazard Identification Number: 90
- Labels: 9

**ADR**
- Packing group: III
- Classification Code: M6
- Hazard Identification Number: 90
- Labels: 9

**RID**
- Packing group: III
- Classification Code: M6
- Hazard Identification Number: 90
- Labels: 9
- Tunnel restriction code: (-)

**IMDG**
- Packing group: III
- Labels: 9

**IATA**
- Packing instruction (cargo aircraft): 964
- Packing instruction (LQ): Y964
- Packing group: III
- Labels: Miscellaneous

**IATA (Cargo)**
- Packing instruction (passenger aircraft): 964
- Packing instruction (LQ): Y964
- Packing group: III
- Labels: Miscellaneous

**IATA (Passenger)**

### Environmental hazards

**ADN**
- Environmentally hazardous: yes

**ADR**
- Environmentally hazardous: yes

**RID**
- Environmentally hazardous: yes

**IMDG**
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Abamectin Liquid Formulation

Marine pollutant : yes

IATA (Passenger) Environmentally hazardous : yes
IATA (Cargo) Environmentally hazardous : yes

14.6 Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments
Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII) : Conditions of restriction for the following entries should be considered: Number on list 3
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59). : Not applicable
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer : Not applicable
Regulation (EU) 2019/1021 on persistent organic pollutants (recast) : Not applicable
Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals : Not applicable
REACH - List of substances subject to authorisation (Annex XIV) : Not applicable

<table>
<thead>
<tr>
<th>E1</th>
<th>ENVIRONMENTAL HAZARDS</th>
<th>Quantity 1</th>
<th>Quantity 2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>100 t</td>
<td>200 t</td>
</tr>
</tbody>
</table>

Other regulations:
Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:

AICS : not determined
DSL : not determined
IECSC : not determined

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.
SECTION 16: Other information

Other information

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-statements

H300 : Fatal if swallowed.
H311 : Toxic in contact with skin.
H330 : Fatal if inhaled.
H361fd : Suspected of damaging fertility. Suspected of damaging the unborn child.
H372 : Causes damage to organs through prolonged or repeated exposure if swallowed.
H400 : Very toxic to aquatic life.
H410 : Very toxic to aquatic life with long lasting effects.

Full text of other abbreviations

Acute Tox. : Acute toxicity
Aquatic Acute : Short-term (acute) aquatic hazard
Aquatic Chronic : Long-term (chronic) aquatic hazard
Repr. : Reproductive toxicity
STOT RE : Specific target organ toxicity - repeated exposure
Abamectin Liquid Formulation

Version: 4.7
Revision Date: 27.08.2021
SDS Number: 1228550-00015
Date of last issue: 26.04.2021
Date of first issue: 18.01.2017

Further information
Sources of key data used to compile the Safety Data Sheet:

Classification of the mixture:
<table>
<thead>
<tr>
<th>Acute Tox. 4</th>
<th>H332</th>
<th>Calculation method</th>
</tr>
</thead>
<tbody>
<tr>
<td>STOT RE 2</td>
<td>H373</td>
<td>Calculation method</td>
</tr>
<tr>
<td>Aquatic Acute 1</td>
<td>H400</td>
<td>Calculation method</td>
</tr>
<tr>
<td>Aquatic Chronic 1</td>
<td>H410</td>
<td>Calculation method</td>
</tr>
</tbody>
</table>

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN